



Figure S2. Effect of dasatinib (DAS), ponatinib (PON) and IPA-3 on cell viability of CML-BP cell lines. (A) The cells were treated for 24 h with the indicated doses of TKIs and IPA-3 individually and in combination followed by MTT assay to test cell viability. Each point represents the mean \pm standard deviation (SD) ($n \geq 4$), * $p < 0.05$ in comparison with TKI. (B) Combination index (CI) values with a 95% confidence interval at all effective levels indicate the nature of the interactions (CI = 1 = additivity, CI < 1 = synergy, CI > 1 = antagonism). Fa is the fraction of cells affected by combination treatment.